genial
发表于 2025-3-21 19:34:42
书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0232020<br><br> <br><br>书目名称Compulsory Patent Licensing and Access to Medicines: A Silver Bullet Approach to Public Health?读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0232020<br><br> <br><br>
Notify
发表于 2025-3-21 23:11:31
International Patent Law and the Pharmaceutical Industry,ry, and to highlight the benefits and disbenefits associated with patent innovation. As will be critically evaluated in this chapter, the international patent system, from the Paris Convention to the TRIPS Agreement, has been significantly bolstered. To the world’s pharmaceutical industry, TRIPS is
背景
发表于 2025-3-22 03:05:10
http://reply.papertrans.cn/24/2321/232020/232020_3.png
Heterodoxy
发表于 2025-3-22 06:29:43
http://reply.papertrans.cn/24/2321/232020/232020_4.png
灵敏
发表于 2025-3-22 10:36:54
http://reply.papertrans.cn/24/2321/232020/232020_5.png
Medley
发表于 2025-3-22 14:37:21
Access to Medicines and Multilateral Organisations,ich in one way or another all take part in the ongoing deliberations of access to medicine. This chapter aims at establishing and analysing the stance of the four aforementioned organisations and determines to what extent their roles influence the world’s access to medicine policies, particularly th
Medley
发表于 2025-3-22 19:26:21
http://reply.papertrans.cn/24/2321/232020/232020_7.png
meritorious
发表于 2025-3-22 23:58:21
IPS flexibilities.This timely monograph focuses on India and Brazil’s use of compulsory licensing, one of the most significant and controversial TRIPS flexibilities. This is a topical work at this critical time when the COVID-19 has stirred up the debate about compulsory licensing and access to medi
neolith
发表于 2025-3-23 01:34:22
https://doi.org/10.1007/978-3-531-91596-8wned by Bayer. While this historic decision seemed to herald a new era of compulsory licensing in the region, the Controller, unexpectedly, turned down two subsequent applications made by private companies, in late 2013 and early 2016. By examine these three applications, this chapter is to yield new insights into the Indian situation.
逢迎白雪
发表于 2025-3-23 09:12:14
The Indian Case Study of Compulsory Licensing,wned by Bayer. While this historic decision seemed to herald a new era of compulsory licensing in the region, the Controller, unexpectedly, turned down two subsequent applications made by private companies, in late 2013 and early 2016. By examine these three applications, this chapter is to yield new insights into the Indian situation.